Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Chief Operating Officer | February 15, 2018 | February 23, 2018 |
| Quince Therapeutics, Inc.CRTX · Entity 7403 | Director | June 08, 2020 | June 09, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date February 15, 2018 · Filed February 23, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,612 |
Ending reported balance
After 2018-02-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-02-15 · Grant · Acquired 340 · Balance 16,152 F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Row 2 · 2018-02-21 · Grant · Acquired 9,460 · Balance 25,612 F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.
F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively.
Quince Therapeutics, Inc.
Report date June 08, 2020 · Filed June 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.73 · Expires 2030-06-07 | Direct | 11,029 |
Reported balance
After 2020-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-08 · Grant · Acquired 11,029 · Balance 11,029 F1: This option shall fully vest on the one-year anniversary of the grant date, subject to the reporting person's continued services as a member of the board of directors of Cortexyme, Inc. through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall fully vest on the one-year anniversary of the grant date, subject to the reporting person's continued services as a member of the board of directors of Cortexyme, Inc. through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 23, 2013 Filed Sep 25, 2013 22:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Optin (right to buy) · Derivative | 87,492 | $0.00 Strike: $16.40 | $0.00 |
DisclosureSEC source: 0001179110-13-014616 · edgar.xml · derivative · entry 6 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 432,508 Underlying: Common Stock · 87,492 shares Expires 2017-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| September 23, 2013 Filed Sep 25, 2013 22:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Optin (right to buy) · Derivative | 12,508 | $0.00 Strike: $8.01 | $0.00 |
DisclosureSEC source: 0001179110-13-014616 · edgar.xml · derivative · entry 5 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,508 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| September 23, 2013 Filed Sep 25, 2013 22:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 31,385 | $63.11 | $1,980,745.01 |
DisclosureSEC source: 0001179110-13-014616 · edgar.xml · nonDerivative · entry 4 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,840 F4 · price: Sale prices reported for the transactions reported here range from $63.01 to $63.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request Read SEC document |
| September 23, 2013 Filed Sep 25, 2013 22:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 68,615 | $62.78 | $4,307,443.86 |
DisclosureSEC source: 0001179110-13-014616 · edgar.xml · nonDerivative · entry 3 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,225 F3 · price: Sale prices reported for the transactions reported here range from $62.50 to $63.00. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| September 23, 2013 Filed Sep 25, 2013 22:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 12,508 | $8.01 | $100,126.54 |
DisclosureSEC source: 0001179110-13-014616 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 23, 2013 Filed Sep 25, 2013 22:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 87,492 | $16.40 | $1,434,431.34 |
DisclosureSEC source: 0001179110-13-014616 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 22:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 15,132 | $45.40 | $686,992.80 |
DisclosureSEC source: 0001179110-13-004726 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,840 Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 22:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 29,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-004726 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,972 F1 · shares: Vesting of performance share awards on March 6, 2013 F2 · balance_after: Amount of securities beneficially owned following the reported transaction includes 968 shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on February 15, 2013. Read SEC document |
| February 01, 2013 Filed Feb 5, 2013 21:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Optin (right to buy) · Derivative | 108,470 | $0.00 Strike: $40.56 | $0.00 |
DisclosureSEC source: 0001179110-13-001927 · edgar.xml · derivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,470 Underlying: Common Stock · 108,470 shares Expires 2023-02-01 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 30, 2013 Filed Jan 24, 2014 22:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 21,332 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-001364 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,172 F1 · shares: Represents shares of the Issuer's common stock subject to a specific tranche of the performance share award made to the Reporting Person on January 26, 2012. Such tranche of shares was subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was deemed satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be actually issued to the Reporting Person until such individual satisfies the applicable service-vesting requirement by continuing in the Issuer's employ through December 31, 2014. Read SEC document |
| November 19, 2012 Filed Nov 20, 2012 19:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Optin (right to buy) · Derivative | 360,000 | $0.00 Strike: $29.01 | $0.00 |
DisclosureSEC source: 0001179110-12-016296 · edgar.xml · derivative · entry 10 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 360,000 shares Expires 2016-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| November 19, 2012 Filed Nov 20, 2012 19:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 360,000 | $74.31 | $26,751,312.00 |
DisclosureSEC source: 0001179110-12-016296 · edgar.xml · nonDerivative · entry 6 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,502 F3 · price: Sale prices reported for the transactions reported here range from $74.30 to $74.40. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 19, 2012 Filed Nov 20, 2012 19:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 360,000 | $29.01 | $10,441,800.00 |
DisclosureSEC source: 0001179110-12-016296 · edgar.xml · nonDerivative · entry 5 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 433,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2012 Filed Nov 20, 2012 19:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Optin (right to buy) · Derivative | 71,876 | $0.00 Strike: $17.68 | $0.00 |
DisclosureSEC source: 0001179110-12-016296 · edgar.xml · derivative · entry 9 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,876 shares Expires 2014-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| November 16, 2012 Filed Nov 20, 2012 19:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 22,624 | $0.00 Strike: $17.68 | $0.00 |
DisclosureSEC source: 0001179110-12-016296 · edgar.xml · derivative · entry 8 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,624 shares Expires 2014-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| November 16, 2012 Filed Nov 20, 2012 19:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 6,246 | $0.00 Strike: $16.01 | $0.00 |
DisclosureSEC source: 0001179110-12-016296 · edgar.xml · derivative · entry 7 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,246 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| November 16, 2012 Filed Nov 20, 2012 19:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100,746 | $74.66 | $7,521,958.30 |
DisclosureSEC source: 0001179110-12-016296 · edgar.xml · nonDerivative · entry 4 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,502 F2 · price: Sale prices reported for the transactions reported here range from $74.60 to $74.80. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 16, 2012 Filed Nov 20, 2012 19:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 6,246 | $16.01 | $99,998.46 |
DisclosureSEC source: 0001179110-12-016296 · edgar.xml · nonDerivative · entry 3 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2012 Filed Nov 20, 2012 19:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 71,876 | $17.68 | $1,270,408.30 |
DisclosureSEC source: 0001179110-12-016296 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,002 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2012 Filed Nov 20, 2012 19:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 22,624 | $17.68 | $399,879.20 |
DisclosureSEC source: 0001179110-12-016296 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,126 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2012 Filed Jul 3, 2012 23:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 733 | $29.02 | $21,270.93 |
DisclosureSEC source: 0001179110-12-011182 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,502 F1 · kind: Amount of securities beneficially owned following the reported transaction includes 733 shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on June 29, 2012. Read SEC document |
| March 12, 2012 Filed Mar 14, 2012 23:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 10,230 | $46.16 | $472,216.80 |
DisclosureSEC source: 0001179110-12-005058 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,769 Read SEC document |
| March 12, 2012 Filed Mar 14, 2012 23:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 23,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-005058 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,999 F1 · shares: Issuance of common stock upon vesting of performance share awards on March 12, 2012 Read SEC document |
| January 26, 2012 Filed Jan 31, 2012 00:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 94,000 | $0.00 Strike: $48.59 | $0.00 |
DisclosureSEC source: 0001179110-12-001337 · edgar.xml · derivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,000 Underlying: Common Stock · 94,000 shares Expires 2022-01-26 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 15, 2011 Filed Mar 17, 2011 23:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 8,115 | $39.79 | $322,895.85 |
DisclosureSEC source: 0001179110-11-005181 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,101 Read SEC document |
| March 15, 2011 Filed Mar 17, 2011 23:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 19,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-11-005181 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,216 F1 · shares: Issuance of common stock upon vesting of certain performance share awards on March 15, 2011. Read SEC document |
| March 15, 2011 Filed Apr 6, 2011 23:35 UTC Amendment | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 9,924 | $39.79 | $394,875.96 |
DisclosureSEC source: 0001179110-11-006159 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,167 F2 · shares: The transactions listed in Table 1 are restated in its entirety to show the correct number of shares issued and beneficially owned. Read SEC document |
| March 15, 2011 Filed Apr 6, 2011 23:35 UTC Amendment | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 23,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-11-006159 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,091 F1 · shares: Issuance of common stock upon vesting of certain performance share awards on March 15, 2011. F2 · shares: The transactions listed in Table 1 are restated in its entirety to show the correct number of shares issued and beneficially owned. Read SEC document |
| January 20, 2011 Filed Jan 25, 2011 00:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 119,000 | $0.00 Strike: $38.17 | $0.00 |
DisclosureSEC source: 0001179110-11-001274 · edgar.xml · derivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,000 Underlying: Common Stock · 119,000 shares Expires 2021-01-20 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on January 20, 2012, the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested on January 20, 2015. The options expire on January 20, 2021. Read SEC document |
| August 24, 2010 Filed Aug 26, 2010 14:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $17.68 | $0.00 |
DisclosureSEC source: 0001179110-10-013209 · edgar.xml · derivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,876 Underlying: Common Stock · 10,000 shares Expires 2014-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options had a 5-year vesting schedule. 20% of the options vested on November 2, 2005, the first anniversary of the date of the grant. The balance vested 5% every three months thereafter until fully vested on November 2, 2009. The options expire on November 2, 2014. Read SEC document |
| August 24, 2010 Filed Aug 26, 2010 14:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,000 | $17.68 | $176,750.00 |
DisclosureSEC source: 0001179110-10-013209 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Amount of securities beneficially owned following the reported transaction includes 577 shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on June 30, 2010. Read SEC document |
| March 08, 2010 Filed Mar 11, 2010 01:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 11,083 | $47.01 | $521,011.83 |
DisclosureSEC source: 0001179110-10-004953 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,264 Read SEC document |
| March 08, 2010 Filed Mar 11, 2010 01:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-004953 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,347 F1 · shares: Issuance of common stock upon vesting of certain performance share awards on March 8, 2010. Read SEC document |
| January 28, 2010 Filed Feb 2, 2010 00:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 87,000 | $0.00 Strike: $47.51 | $0.00 |
DisclosureSEC source: 0001179110-10-001744 · edgar.xml · derivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,000 Underlying: Common Stock · 87,000 shares Expires 2020-01-28 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on January 28, 2011 the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 28, 2015. Read SEC document |
| December 01, 2009 Filed Dec 3, 2009 20:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 31,914 | $0.00 Strike: $17.68 | $0.00 |
DisclosureSEC source: 0001179110-09-016227 · edgar.xml · derivative · entry 5 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,876 Underlying: Common Stock · 31,914 shares Expires 2014-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options vested on November 2, 2005, the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on November 2, 2009. Read SEC document |
| December 01, 2009 Filed Dec 3, 2009 20:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 43,086 | $0.00 Strike: $16.01 | $0.00 |
DisclosureSEC source: 0001179110-09-016227 · edgar.xml · derivative · entry 4 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,254 Underlying: Common Stock · 43,086 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options vested on January 26, 2006, the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 26, 2010. Read SEC document |
| December 01, 2009 Filed Dec 3, 2009 20:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 75,000 | $45.80 | $3,435,142.50 |
DisclosureSEC source: 0001179110-09-016227 · edgar.xml · nonDerivative · entry 3 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,347 F3 · price: Sale prices reported for the transactions reported here range from $45.64 to $45.97. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| December 01, 2009 Filed Dec 3, 2009 20:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 31,914 | $17.68 | $564,079.95 |
DisclosureSEC source: 0001179110-09-016227 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2009 Filed Dec 3, 2009 20:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 43,086 | $16.01 | $689,806.86 |
DisclosureSEC source: 0001179110-09-016227 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2009 Filed Oct 7, 2009 22:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $17.68 | $0.00 |
DisclosureSEC source: 0001179110-09-014342 · edgar.xml · derivative · entry 5 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,790 Underlying: Common Stock · 20,000 shares Expires 2014-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options vested on November 2, 2005, the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on November 2, 2009. Read SEC document |
| October 05, 2009 Filed Oct 7, 2009 22:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.01 | $0.00 |
DisclosureSEC source: 0001179110-09-014342 · edgar.xml · derivative · entry 4 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,340 Underlying: Common Stock · 10,000 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options vested on January 26, 2006, the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 26, 2010. Read SEC document |
| October 05, 2009 Filed Oct 7, 2009 22:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 30,000 | $44.70 | $1,341,105.00 |
DisclosureSEC source: 0001179110-09-014342 · edgar.xml · nonDerivative · entry 3 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,347 F3 · price: Sale prices reported for the transactions reported here range from $44.60 to $44.81. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 05, 2009 Filed Oct 7, 2009 22:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 20,000 | $17.68 | $353,500.00 |
DisclosureSEC source: 0001179110-09-014342 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2009 Filed Oct 7, 2009 22:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,000 | $16.01 | $160,100.00 |
DisclosureSEC source: 0001179110-09-014342 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2009 Filed Jul 11, 2009 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $17.68 | $0.00 |
DisclosureSEC source: 0001179110-09-010826 · edgar.xml · derivative · entry 5 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,618 Underlying: Common Stock · 20,000 shares Expires 2014-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options vested on November 2, 2005, the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on November 2, 2009. Read SEC document |
| July 09, 2009 Filed Jul 11, 2009 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.01 | $0.00 |
DisclosureSEC source: 0001179110-09-010826 · edgar.xml · derivative · entry 4 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,086 Underlying: Common Stock · 10,000 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options vested on January 26, 2006, the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 26, 2010. Read SEC document |
| July 09, 2009 Filed Jul 11, 2009 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 30,000 | $44.63 | $1,338,990.00 |
DisclosureSEC source: 0001179110-09-010826 · edgar.xml · nonDerivative · entry 3 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,347 F3 · price: Sale prices reported for the transactions reported here range from $44.50 to $44.70. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 09, 2009 Filed Jul 11, 2009 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 20,000 | $17.68 | $353,500.00 |
DisclosureSEC source: 0001179110-09-010826 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2009 Filed Jul 11, 2009 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,000 | $16.01 | $160,100.00 |
DisclosureSEC source: 0001179110-09-010826 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Amount of securities beneficially owned following the reported transaction includes 479 shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on June 30, 2009. Read SEC document |
| April 03, 2009 Filed Apr 7, 2009 22:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $17.68 | $0.00 |
DisclosureSEC source: 0001179110-09-006327 · edgar.xml · derivative · entry 6 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,790 Underlying: Common Stock · 20,000 shares Expires 2014-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options vested on November 2, 2005, the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on November 2, 2009. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.